

Table 1.7 FDA-Approved Anticancer Drugs Described in Chapters 10 and 11—cont'd

Drug	Mechanism of Action	Approval Date (First Indication)
Gefitinib (Iressa [®])	EGFR inhibitor	2003
Erlotinib (Tarceva [®])	EGFR inhibitor	2004
Cetuximab (IMC-C225, Erbitux [®])	EGFR inhibitor	2004
Bevacizumab (Avastin [®])	VEGF inhibitor	2004
Sorafenib (Nexavar [®])	Multikinase inhibitor	2005
Dasatinib (Sprycel [®])	Bcr-Abl and Src inhibitor	2006
Sunitinib (Sutent [®])	VEGFR inhibitor	2006
Panitumumab (Vectibix [®])	EGFR inhibitor	2006
Nilotinib (Tasigna [®])	Bcr-Abl inhibitor	2007
Temsirolimus (Torisel [®])	mTOR inhibitor	2007
Lapatinib (Tyverb [®])	EGFR and HER-2 inhibitor	2007
Plerixafor (Mozobil [®])	CXCR4 inhibition	2008
Pazopanib (Votrient [®])	VEGFR inhibitor	2009
Everolimus (Afinitor [®])	mTOR inhibitor	2009
Vemurafenib (Zelboraf [®])	Raf inhibitor	2011
Crizotinib (PF-02341066, Xalkori [®])	ALK and c-Met inhibitor	2011
Vandetanib (Caprelsa [®])	VEGFR and EGFR inhibitor	2011
Ruxolitinib (Jakavi [®])	JAK inhibitor	2011
Bosutinib (SKI-606, Bosulif [®])	Bcr-Abl and Src inhibitor	2012
Cabozantinib (Cometriq [®])	Inhibitor of VEGFR and related receptors	2012
Ponatinib (AP24534, Iclusig [®])	Bcr-Abl inhibitor	2012
Regorafenib (Stivarga [®])	Raf inhibitor	2012
Omacetaxine mepesuccinate (Synribo [®])	Inhibitor of protein synthesis	2012
Pertuzumab (2C4, Perjeta [®])	HER-2 inhibitor	2012
Axitinib (Inlyta [®])	Inhibitor of VEGFR and related receptors	2012
Dabrafenib (Tafinlar [®])	Raf inhibitor	2013
Trametinib (Mekinist [®])	MEK inhibitor	2013
Afatinib (Gilotrif [®])	EGFR inhibitor	2013
Ibrutinib (PCI-32765, Imbruvica [®])	Bruton's tyrosine kinase inhibitor	2013
Idelalisib (Zydelig [®])	PI3K inhibitor	2014
Ceritinib (Zykadia [®])	ALK inhibitor	2014
Bortezomib (Velcade [®])	Proteasome inhibitor	2003
Thalidomide (Thalomid [®])	Angiogenesis inhibition	2006
Lenalidomide (Revlimid [®])	Angiogenesis inhibition	2006
Carfilzomib (Krypolis [®])	Proteasome inhibitor	2012
Vismodegib (GDC-0449, Erivedge [®])	Smo receptor inhibitor	2012
Pomalidomide (CC-4047, Imnovid [®])	Angiogenesis inhibition	2013
Lenvatinib (Lenvima [®])	VEGFR-2 inhibitor	2015